drugset / Trial / NCT02005822

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment

NCT02005822

Non-randomizedParallel-groupSingle-blindTreatment

Summary

The objective of the trial is to investigate whether early treatment with oral valganciclovir of infants with both congenital cytomegalovirus infection and sensorineural hearing loss can prevent progression of hearing loss.

Timeline

Start
2013-10-22
Primary completion
2018-05-17
Completion
2018-05-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule 16 mg/kg Oral